Interstitial Lung Disease Section
-
Update on the evaluation and management of interstitial lung abnormalities
New guidelines from ATS outline the screening and follow-up procedures for interstitial lung abnormalities as well as define who is at higher risk for progressing to ILD.
-
Artificial intelligence and its application in interstitial lung disease
AI shows promise in improving ILD diagnosis, prognosis, and treatment decisions by analyzing complex data and patterns, though certain limitations hinder its clinical adoption.
-
Short telomere length and immunosuppression: Updates in nonidiopathic pulmonary fibrosis, interstitial lung disease
Interstitial lung diseases (ILDs) are a diverse group of relentlessly progressive fibroinflammatory disorders. Pharmacotherapy includes antifibrotics and immunosuppressants as foundational strategies to mitigate loss of lung function. There has been […]
-
Updates in evidence for rituximab in interstitial lung disease
Interstitial lung diseases (ILD) are a heterogeneous group of fibro-inflammatory disorders that can be progressive despite available therapies. The cornerstones of pharmacologic therapy include immunosuppression and antifibrotics. Data on the […]
